NO20062256L - Hydroksyalkylsubstituerte pyrido-7-pyrimidin-7-oner - Google Patents

Hydroksyalkylsubstituerte pyrido-7-pyrimidin-7-oner

Info

Publication number
NO20062256L
NO20062256L NO20062256A NO20062256A NO20062256L NO 20062256 L NO20062256 L NO 20062256L NO 20062256 A NO20062256 A NO 20062256A NO 20062256 A NO20062256 A NO 20062256A NO 20062256 L NO20062256 L NO 20062256L
Authority
NO
Norway
Prior art keywords
pyrimidin
hydroxyalkyl
ones
substituted pyrido
formula
Prior art date
Application number
NO20062256A
Other languages
English (en)
Inventor
David Michael Goldstein
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of NO20062256L publication Critical patent/NO20062256L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Immunology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Foreliggende oppfinnelse tilveiebringer en forbindelse med formel I hvor X1, Ar1, R1 og R2 er som definert her samt preparater omfattende samme. Foreliggende oppfinnelse tilveiebringer også fremgangsmåter for anvendelse av forbindelser med formel I ved behandling av p38-medierte lidelser hos en pasient.
NO20062256A 2003-11-13 2006-05-19 Hydroksyalkylsubstituerte pyrido-7-pyrimidin-7-oner NO20062256L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US51978903P 2003-11-13 2003-11-13
PCT/EP2004/012475 WO2005047284A1 (en) 2003-11-13 2004-11-04 Hydroxyalkyl substituted pyrido-7-pyrimidin-7-ones

Publications (1)

Publication Number Publication Date
NO20062256L true NO20062256L (no) 2006-06-06

Family

ID=34590444

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20062256A NO20062256L (no) 2003-11-13 2006-05-19 Hydroksyalkylsubstituerte pyrido-7-pyrimidin-7-oner

Country Status (27)

Country Link
US (2) US7348331B2 (no)
EP (1) EP1685131B1 (no)
JP (1) JP4616839B2 (no)
KR (1) KR100816321B1 (no)
CN (1) CN100455582C (no)
AR (1) AR046705A1 (no)
AT (1) ATE356124T1 (no)
AU (1) AU2004289428B2 (no)
BR (1) BRPI0416030A (no)
CA (1) CA2544247A1 (no)
CO (1) CO5690600A2 (no)
DE (1) DE602004005238T2 (no)
DK (1) DK1685131T3 (no)
ES (1) ES2281843T3 (no)
HK (1) HK1099021A1 (no)
HR (1) HRP20070132T3 (no)
IL (1) IL175284A0 (no)
MY (1) MY141011A (no)
NO (1) NO20062256L (no)
NZ (1) NZ546634A (no)
PL (1) PL1685131T3 (no)
PT (1) PT1685131E (no)
RU (1) RU2348632C2 (no)
SI (1) SI1685131T1 (no)
TW (1) TWI349670B (no)
WO (1) WO2005047284A1 (no)
ZA (1) ZA200603829B (no)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008011032A1 (en) 2006-07-17 2008-01-24 Amgen Inc. Quinazoline and pyridopyrimidine derivatives as p38 kinase inhibitors
CN101568518A (zh) * 2006-12-22 2009-10-28 霍夫曼-拉罗奇有限公司 用于氨基亚烷基二醇合成的化合物和方法
CA2690327A1 (en) * 2007-06-15 2008-12-18 Thomas P. Cleary A novel process for the preparation of 3-amino-pentan-1,5-diol
CA2784749C (en) * 2009-12-18 2017-12-12 E. Premkumar Reddy Substituted pyrido[2,3-d]pyrimidin-7(8h)-ones and therapeutic uses thereof
BR112016017137B1 (pt) * 2014-02-07 2022-10-11 Principia Biopharma, Inc Composto e/ou sal farmaceuticamente aceitável do mesmo e composições farmacêuticas
KR102183356B1 (ko) 2015-08-11 2020-11-27 프린시피아 바이오파마, 인코퍼레이티드 Fgfr 억제제를 제조하기 위한 방법
CN105418609B (zh) * 2015-12-31 2017-06-23 山东大学 4‑(1,2,3‑三氮唑取代苯胺基)‑吡啶骈嘧啶酮衍生物及其制备方法与应用
US20190060286A1 (en) 2016-02-29 2019-02-28 University Of Florida Research Foundation, Incorpo Chemotherapeutic Methods
CA3025377A1 (en) 2016-06-02 2017-12-07 Abbvie Inc. Glucocorticoid receptor agonist and immunoconjugates thereof
WO2017211830A1 (en) 2016-06-08 2017-12-14 Support-Venture Gmbh Pharmaceutical combinations for treating cancer
CN109562105A (zh) 2016-08-17 2019-04-02 企业支持有限责任公司 预防或治疗听力损失的方法
EA201992004A1 (ru) * 2017-04-04 2020-02-20 Кинарус Аг Способы предотвращения или лечения офтальмологических заболеваний
US10342786B2 (en) 2017-10-05 2019-07-09 Fulcrum Therapeutics, Inc. P38 kinase inhibitors reduce DUX4 and downstream gene expression for the treatment of FSHD
CN114732910A (zh) 2017-10-05 2022-07-12 弗尔康医疗公司 P38激酶抑制剂降低dux4和下游基因表达以用于治疗fshd
RU2020117698A (ru) 2017-12-01 2022-01-04 Эббви Инк. Агонист глюкокортикоидного рецептора и его иммуноконъюгаты
HUE060654T2 (hu) 2018-05-21 2023-04-28 Nerviano Medical Sciences Srl Heterokondelzált piridonvegyületek és azok IDH-gátlóként történõ alkalmazása
US20210267983A1 (en) 2018-07-13 2021-09-02 Kinarus Ag Combinations of ppar agonists and p38 kinase inhibitors for preventing or treating fibrotic diseases
JP2022554364A (ja) 2019-11-08 2022-12-28 ネルビアーノ・メデイカル・サイエンシーズ・エツセ・エルレ・エルレ ｇｅｍ－二置換複素環式化合物及びＩＤＨ阻害剤としてのその使用
WO2022034031A1 (en) 2020-08-11 2022-02-17 Kinarus Ag Methods of preventing or treating covid-19 and related viral diseases or disorders

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4215216A (en) 1979-04-18 1980-07-29 American Home Products Corporation 7,8-Dihydro-2,5,8-trisubstituted-7-oxo-pyrido[2,3-d]pyrimidine-6-carboxylic acid derivatives
US5037826A (en) 1986-10-15 1991-08-06 Schering Corporation 1-substituted naphthyridine and pyridopyrazine derivatives
EP0278686A1 (en) 1987-02-07 1988-08-17 The Wellcome Foundation Limited Pyridopyrimidines methods for their preparation and pharmaceutical formulations thereof
WO1993017682A1 (en) 1992-03-04 1993-09-16 Abbott Laboratories Angiotensin ii receptor antagonists
TJ342B (en) 1994-11-14 2002-10-06 Warner Lambert Co Derivatives of 6-aryl pyrido Ä2,3-dÜ pyrimidines and naphthyridines pharmaceutical composition possess inhibiting effect of cellular proliferation pr ovoking protein tyrosine kinase and method of inhibiting cellular proliferation
IL115256A0 (en) 1994-11-14 1995-12-31 Warner Lambert Co 6-Aryl pyrido (2,3-d) pyrimidines and naphthyridines and their use
US5620981A (en) 1995-05-03 1997-04-15 Warner-Lambert Company Pyrido [2,3-D]pyrimidines for inhibiting protein tyrosine kinase mediated cellular proliferation
IL117923A (en) 1995-05-03 2000-06-01 Warner Lambert Co Anti-cancer pharmaceutical compositions containing polysubstituted pyrido¬2,3-d¾pyrimidine derivatives and certain such novel compounds
EP0964864B1 (en) 1997-02-05 2008-04-09 Warner-Lambert Company LLC Pyrido 2,3-d pyrimidines and 4-aminopyrimidines as inhibitors of cellular proliferation
US5945422A (en) 1997-02-05 1999-08-31 Warner-Lambert Company N-oxides of amino containing pyrido 2,3-D! pyrimidines
EP1080092B1 (en) 1998-05-26 2008-07-23 Warner-Lambert Company LLC Bicyclic pyrimidines and bicyclic 3,4-dihydropyrimidines as inhibitors of cellular proliferation
US7053070B2 (en) 2000-01-25 2006-05-30 Warner-Lambert Company Pyrido[2,3-d]pyrimidine-2,7-diamine kinase inhibitors
JP2003523358A (ja) 2000-01-27 2003-08-05 ワーナー−ランバート・カンパニー、リミテッド、ライアビリティ、カンパニー 神経変性疾患の治療のためのピリドピリミジノン誘導体
IL151480A0 (en) 2000-03-06 2003-04-10 Warner Lambert Co 5-alkylpyrido[2,3-d] pyrimidines tyrosine kinase inhibitors
US6518276B2 (en) 2000-08-31 2003-02-11 Syntex (U.S.A.) Llc 7-oxo-pyridopyrimidines (II)
CN1275964C (zh) * 2000-08-31 2006-09-20 霍夫曼-拉罗奇有限公司 作为细胞增殖抑制剂的7－氧代吡啶并嘧啶
ATE305303T1 (de) * 2001-02-12 2005-10-15 Hoffmann La Roche 6-substituierte pyridopyrimidine
CN101001857B (zh) * 2002-01-22 2011-06-22 沃尼尔·朗伯有限责任公司 2-(吡啶-2-基氨基)-吡啶并[2,3-d]嘧啶-7-酮
FR2897336B1 (fr) 2006-02-10 2010-07-30 Ranger France Support d'aile pour vehicule automobile

Also Published As

Publication number Publication date
TW200526657A (en) 2005-08-16
ES2281843T3 (es) 2007-10-01
ATE356124T1 (de) 2007-03-15
AU2004289428B2 (en) 2010-06-03
JP4616839B2 (ja) 2011-01-19
SI1685131T1 (sl) 2007-06-30
RU2006120486A (ru) 2008-01-20
IL175284A0 (en) 2006-09-05
CO5690600A2 (es) 2006-10-31
CN100455582C (zh) 2009-01-28
AR046705A1 (es) 2005-12-21
EP1685131B1 (en) 2007-03-07
BRPI0416030A (pt) 2007-01-02
PL1685131T3 (pl) 2007-08-31
US20080119497A1 (en) 2008-05-22
US20050107408A1 (en) 2005-05-19
US7348331B2 (en) 2008-03-25
HK1099021A1 (en) 2007-08-03
KR20060086417A (ko) 2006-07-31
TWI349670B (en) 2011-10-01
MY141011A (en) 2010-02-25
AU2004289428A1 (en) 2005-05-26
US7750016B2 (en) 2010-07-06
HRP20070132T3 (en) 2007-05-31
DE602004005238T2 (de) 2007-11-08
PT1685131E (pt) 2007-05-31
RU2348632C2 (ru) 2009-03-10
DE602004005238D1 (de) 2007-04-19
NZ546634A (en) 2010-01-29
CN1882585A (zh) 2006-12-20
CA2544247A1 (en) 2005-05-26
JP2007510686A (ja) 2007-04-26
KR100816321B1 (ko) 2008-03-24
WO2005047284A1 (en) 2005-05-26
DK1685131T3 (da) 2007-07-09
ZA200603829B (en) 2007-10-31
EP1685131A1 (en) 2006-08-02

Similar Documents

Publication Publication Date Title
NO20062256L (no) Hydroksyalkylsubstituerte pyrido-7-pyrimidin-7-oner
DE60214703D1 (de) Thiazolverbindungen, die sich als inhibitoren von proteinkinasen eignen
NO20064000L (no) Heteroarylkoblede pyrazoloderivater
NO20056192L (no) Kapaseinhibitorer og anvendelse derav
NO20063479L (no) Fosfonater, monofosfonamidater og bis-fosfonamidater for behandling av virussykdommer
NO20062561L (no) Kinoliner nyttige for behandling av kardiovaskulaere sykdommer
NO20051100L (no) Pyrazolsammensetninger anvendelige som GSK-3-inhibitorer
ATE371656T1 (de) Heteroaryl-pyrimidinderivate als jak-inhibitoren
ATE440087T1 (de) 2,4-diaminopyrimidinderivate, die sich als inhibitoren von pkc-theta eignen
ATE454378T1 (de) Verbindungen, die sich als inhibitoren vonjak und anderen proteinkinasen eignen
NO20050828L (no) lndol-3-svovelderivater
NO20062335L (no) Nye diazaspiroalkaner og deres anvendelse i behandlingen av CCR8 medierte sykdommer
NO20054905L (no) 2-acylamino-4-fenyltiazolderivater, fremgangsmate for deres fremstilling og anvendelse av de samme som i terapeutika
WO2005046603A3 (en) Pyridine compounds
NO20045677L (no) Inhibitorer av JAK- og CDK2-proteinkinaser
NO20085373L (no) P38 inhibitorer, deres fremstilling og anvendelse
NO20061080L (no) Kondenserte pyramidinforbindelser som inhibitorer av spenningsstyrte ionekanaler
NO20062021L (no) Omleirede pentanoler, fremgangsmpte for fremstilling av dette, og deres anvendelse som antiflogistika
NO20060324L (no) [1,8]Naftyridin-2-oner og relaterte forbindelser for behandling av Schizofreni
NO20053470L (no) Triazolopyridaziner som proteinkinase-inhibitorer
ATE433447T1 (de) Pyrimiidinverbindungen
NO20070557L (no) Ftalazinderivater som PARP-inhibitorer
NO20064015L (no) Kondenserte derivater av pyrazol
NO20070526L (no) Kinazolindionderivater som parp-inhibitorer
NO20066055L (no) Pyridinderivater

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application